Arcturus Therapeutics Ltd. that it is extending its partnership with Takeda Pharmaceutical Company Limited. Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and other gastrointestinal (GI) related disorders using Arcturus's wholly-owned LUNAR lipid-mediated delivery systems and UNA Oligomer chemistry.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.38 USD | +8.55% |
|
+12.90% | -19.51% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.51% | 684M | |
+25.83% | 47.96B | |
+44.64% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- ARCT Stock
- News Arcturus Therapeutics Holdings Inc.
- Arcturus Therapeutics Ltd. Announces Expansion of Collaboration with Takeda Pharmaceutical Company Limited to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis and Other GI Disorders